IS THE CORONA VIRUS LEFT A LEGACY OF PAIN AND SUFFERING?
Abstract
Between 2019-2022,Corona virus infected millions of people. Nearly three years still we are struggling to understand the extent of this pandemic. In December 2019, a novel corona virus called SARS-CoV-2 caused a sequence of acute atypical pneumonia in Wuhan, China.In early January 2020, Chinese scientists isolated corona virus from the patients’ in Wuhan.The outbreak is supposed to have started at a local seafood/wild animal market. The infecting agent was initially called as novel corona virus (2019-nCoV) but was renamed later as Severe Acute Respiratory Syndrome Coro navirus 2 (SARS CoV-2) and the clinical disease was called corona virus disease of 2019 (COVID-19). It was primarily started as a zoonotic transmission, but it was later esteemed that human to human transmission plays a great role in pandemic outbreak globally.COVID-19 infection is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a positive-sense, single-stranded RNA betacoronavirus. The impact of disease affects the lungs, practically every organ in the body is vulnerable to injury caused by the SARS-CoV-2 virus.COVID-19 has affected more than 130 million patients in all age groups.Antibiotics have no role in viral infections.Vaccines are the powerful weapon to fight against Covid.COVID-19 ailment has affected more than 120 million patients in all age groups all over the globe.Certain high-risk groups such as the elderly, human immunodeficiency virus (HIV) patients and those with the front arch of ambulatory are at high risk of severe disease. coronavirus SARS-CoV-2,Molnupiravir,SARS-CoV2 RNA,
References
monocentric cohort study, J Infect Chemother. 2021 Jun; 27(6): 826–833.
, Goyal P., Choi J.J., Pinheiro L.C., Schenck E.J., Chen R. Clinical characteristics of covid-19 in New York city. N Engl J Med. 2020;382(24):2372–2374.
Rhodes N.J., Cruce C.E., O'Donnell J.N., Wunderink R.G., Hauser A.R. Resistance trends and treatment options in Gram-negative ventilator-associated pneumonia. Curr Infect Dis Rep. 2019;20(2):3.
Barth RF.Buja.LM.Parwani.AV.The spectrum of pathological findings in coronavirus disease (COVID-19) and the pathogenesis of SARS-CoV-2.Diagn Pathol
,15.85
rences 1. Ozaras R, Cirpin R, Duran A, et al. Influenza and COVID-19 coinfection: report of six cases and review of the literature. J Med Virol. 2020; 92(11): 2657- 2665.
König B, König W, Arnold R, Werchau H, Ihorst G, Forster J. Prospective study of human metapneumovirus infection in children less than 3 years of age. J Clin Microbiol. 2004; 42(10): 4632- 4635.
Drews AL, Atmar RL, Glezen WP, Baxter BD, Piedra PA, Greenberg SB. Dual respiratory virus infections. Clin Infect Dis. 1997; 25(6): 1421- 1429 4.
.8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223): 497- 506.
Lee N, Chan PK, Yu IT, et al. Co-circulation of human metapneumovirus and SARS-associated coronavirus during a major nosocomial SARS outbreak in Hong Kong. J Clin Virol. 2007; 40(4): 333- 337.
Li-Li Ren 1, Ye-Ming Wang 2 3, Zhi-Qiang Wu 4, Zi- Chun Xiang 1, Li Guo 1, Teng Xu 5, Yong-Zhong Jiang 6, Yan Xiong
Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7:439–50.
Graham RL, Baric RS. Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol. 2010;84:3134–46.
Q. Li et al.
, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199–1207 (2020)
14. C. Huang et al.
, Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet 395, 497–506 (2020
F. Li
, Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3, 237–261 (2016).
16. S. Perlman,
J. Netland
, Coronaviruses post-SARS: Update on replication and pathogenesis. Nat. Rev. Microbiol. 7, 439–450 (2009).
17. L. Du et al.
, The spike protein of SARS-CoV—A target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226–236 (2009).
18. L. Du et al.
, MERS-CoV spike protein: A key target for antivirals. Expert Opin. Ther. Targets 21, 131–143 (2017).
S. Belouzard,
J. K. Millet,
B. N. Licitra,
G. R. Whittaker
, Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4, 1011–1033 (2012).
20. T. Heald-Sargent,
T. Gallagher
, Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses 4, 557–580 (2012).
Stock SJ, et al. SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland. Nat Med. 2022 Jan 13. doi: 10.1038/s41591-021-01666-2
Laumbach RJ, et al. Presence of SARS-CoV-2 Aerosol in Residences of Adults with COVID-19. Ann Am Thorac Soc. 2022 Feb;19(2):338-341. doi: 10.1513/AnnalsATS.202107-847RL.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Education and Research Journal (IERJ)
This work is licensed under a Creative Commons Attribution 4.0 International License.
